Crossmark

Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies

Crossref DOI link: https://doi.org/10.1007/s12094-024-03651-w

Published Online: 2024-08-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gutiérrez Pérez, César https://orcid.org/0009-0001-7179-0906
Lastra Aras, Enrique

Saiz López, Patricia

García Toro, Enrique

Blanco Abad, Carmen

Rodríguez Ledesma, Inmaculada

Pumares González, María

Vela Domínguez, Miriam

Espinosa Cabria, Noelia

Crespo Herrero, Guillermo
Funding

Funding for this research was provided by:

AstraZeneca España
License Information

Text and Data Mining valid from 2024-08-15

Version of Record valid from 2024-08-15
More Information

Article History

Received: 12 June 2024

Accepted: 29 July 2024

First Online: 15 August 2024

Declarations

:

: The authors declare no conflicts of interest.

: The study was approved and authorized by the Ethics Committee of the Hospital Universitario de Burgos.

: All patients provided informed consent for genomic studies and data analysis.

: Not applicable.

Document is current

Any future updates will be listed below